First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival (PFS) and overall survival (OS) compared with sorafenib (Nexavar) in patients with unresectable hepatocellular carcinoma (HCC), according to findings from a phase 3 study (NCT03764293) presented during the 2022 ESMO Congress. 

Please refer to the following website for further details:    

https://www.onclive.com/view/camrelizumab-rivoceranib-combo-significantly-improves-survival-over-sorafenib-in-unresectable-hcc